Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00107237 | AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme | PHASE1 | COMPLETED | 16 | — | — | Oct 1, 2003 | Jun 1, 2006 | Jun 12, 2013 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| AEE788 200 mg + RAD001 5 mg | EXPERIMENTAL | AEE788 200 mg qd, RAD001 5 mg qd |
| AEE788 150 mg + RAD001 5mg | EXPERIMENTAL | AEE788 150 mg qd, RAD001 5 mg qod |
| Name | Type | Description |
|---|---|---|
| AEE788 | DRUG | AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles. |
| everolimus | DRUG | Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs. |
DISEASE CHARACTERISTICS: * Histologically confirmed glioblastoma multiforme, meeting 1 of the following criteria: * Phase I * In first or second recurrence or relapse * At least 1 measurable or evaluable enhancing lesion by gadolinium MRI (Gd-MRI) of the brain within the past 3 weeks ...